238 related articles for article (PubMed ID: 32907836)
1. 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against
Zhao Y; Feng X; Chen Y; Selfridge JE; Gorityala S; Du Z; Wang JM; Hao Y; Cioffi G; Conlon RA; Barnholtz-Sloan JS; Saltzman J; Krishnamurthi SS; Vinayak S; Veigl M; Xu Y; Bajor DL; Markowitz SD; Meropol NJ; Eads JR; Wang Z
Cancer Res; 2020 Nov; 80(21):4815-4827. PubMed ID: 32907836
[No Abstract] [Full Text] [Related]
2. Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Khan N; Jajeh F; Eberhardt EL; Miller DD; Albrecht DM; Van Doorn R; Hruby MD; Maresh ME; Clipson L; Mukhtar H; Halberg RB
Int J Cancer; 2019 Dec; 145(11):3022-3032. PubMed ID: 31018249
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
[TBL] [Abstract][Full Text] [Related]
6. MTORC1/2 Inhibition as a Therapeutic Strategy for
Fricke SL; Payne SN; Favreau PF; Kratz JD; Pasch CA; Foley TM; Yueh AE; Van De Hey DR; Depke MG; Korkos DP; Sha GC; DeStefanis RA; Clipson L; Burkard ME; Lemmon KK; Parsons BM; Kenny PA; Matkowskyj KA; Newton MA; Skala MC; Deming DA
Mol Cancer Ther; 2019 Feb; 18(2):346-355. PubMed ID: 30425131
[No Abstract] [Full Text] [Related]
7. Analysis of anti-tumor effect and mechanism of GLS1 inhibitor CB-839 in colorectal cancer using a stroma-abundant tumor model.
Miyamoto R; Takigawa H; Yuge R; Shimizu D; Ariyoshi M; Otani R; Tsuboi A; Tanaka H; Yamashita K; Hiyama Y; Urabe Y; Ishikawa A; Sentani K; Oka S
Exp Mol Pathol; 2024 Jun; 137():104896. PubMed ID: 38703552
[TBL] [Abstract][Full Text] [Related]
8. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
9. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Sawada N; Kondoh K; Mori K
Oncol Rep; 2007 Oct; 18(4):775-8. PubMed ID: 17786335
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
Bhattacharya B; Akram M; Balasubramanian I; Tam KK; Koh KX; Yee MQ; Soong R
Cancer Biol Ther; 2012 Jan; 13(1):34-42. PubMed ID: 22336586
[TBL] [Abstract][Full Text] [Related]
14. Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in
Miller SA; Policastro RA; Savant SS; Sriramkumar S; Ding N; Lu X; Mohammad HP; Cao S; Kalin JH; Cole PA; Zentner GE; O'Hagan HM
Mol Cancer Res; 2020 Feb; 18(2):264-277. PubMed ID: 31704733
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
[TBL] [Abstract][Full Text] [Related]
16. Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells.
Falcone A; Lencioni M; Brunetti I; Pfanner E; Allegrini G; Antonuzzo A; Andreuccetti M; Malvaldi G; Danesi R; Del Tacca M; Conte PF
Ann Oncol; 1997 Jun; 8(6):539-45. PubMed ID: 9261522
[TBL] [Abstract][Full Text] [Related]
17. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Price TJ; Bruhn MA; Lee CK; Hardingham JE; Townsend AR; Mann KP; Simes J; Weickhardt A; Wrin JW; Wilson K; Gebski V; Van Hazel G; Robinson B; Cunningham D; Tebbutt NC
Br J Cancer; 2015 Mar; 112(6):963-70. PubMed ID: 25742472
[TBL] [Abstract][Full Text] [Related]
18. Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.
Zumwalt TJ; Wodarz D; Komarova NL; Toden S; Turner J; Cardenas J; Burn J; Chan AT; Boland CR; Goel A
Cancer Prev Res (Phila); 2017 Mar; 10(3):208-218. PubMed ID: 28154202
[TBL] [Abstract][Full Text] [Related]
19. Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Morii Y; Tsubaki M; Takeda T; Otubo R; Seki S; Yamatomo Y; Imano M; Satou T; Shimomura K; Nishida S
Eur J Pharmacol; 2021 May; 898():173957. PubMed ID: 33662352
[TBL] [Abstract][Full Text] [Related]
20. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
